ESTA

Establishment Labs Holdings Inc

Add to Watchlist

Advanced Chart

35.960

-5.83(-13.951%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

41.740

Open

38.220

VWAP

37.36

Vol

1.36M

Mkt Cap

1.04B

Low

35.6201

Amount

50.63M

EV/EBITDA(TTM)

Total Shares

27.51M

1.36B

EV/OCF(TTM)

P/S(TTM)

7.03

Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

61.63M

+38.44%

-0.290

-75.63%

52.94M

+31.61%

-0.525

-11.02%

51.10M

+15.83%

-0.565

-8.87%

Estimates Revision

The market is revising Upward the revenue expectations for Establishment Labs Holdings Inc. (ESTA) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by 8.09%.

Revenue Estimates for FY2025

Revise Upward

+0.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.5%

In Past 3 Month

Stock Price

Go Up

+8.09%

In Past 3 Month

7 Analyst Rating

56.12% Upside

Wall Street analysts forecast ESTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESTA is 56.14 USD with a low forecast of 45.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

56.12% Upside

Current: 35.960

Low

45.00

Averages

56.14

High

70.00

56.12% Upside

Current: 35.960

Low

45.00

Averages

56.14

High

70.00

Mizuho

Anthony Petrone

Outperform

maintain

$58 -> $70

2025-07-16

Reason

Mizuho

Anthony Petrone

Price Target

$58 -> $70

2025-07-16

maintain

Outperform

Reason

Mizuho analyst Anthony Petrone raised the firm's price target on Establishment Labs to $70 from $58 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.

Citi

Neutral

maintain

$38 -> $47

2025-07-09

Reason

Citi

Price Target

$38 -> $47

2025-07-09

maintain

Neutral

Reason

Citi raised the firm's price target on Establishment Labs to $47 from $38 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.

Citi

Joanne Wuensch

Neutral

maintain

$38

2025-05-22

Reason

Citi

Joanne Wuensch

Price Target

$38

2025-05-22

maintain

Neutral

Reason

Citi analyst Joanne Wuensch kept a Neutral rating on Establishment Labs with a $38 price target while adding an "upside 90-Day short-term view." Establishment will host an investor meeting on June 12 and generally, stocks trade up into such events, even if it doesn't "hold" the price appreciation afterwards as positioning normalizes, the analyst tells investors in a research note.

BTIG

Buy

maintain

$62

2025-05-16

Reason

BTIG

Price Target

$62

2025-05-16

maintain

Buy

Reason

BTIG reiterates a Buy rating on Establishment Labs with a $62 price target following a transfer of coverage. The firm views the Motiva breast implant as a "disruptive technology" that is likely to replace current implants given its "unique appearance, natural feel and impressive safety profile." The industry has experienced relatively minimal design innovation and discouraging adverse event rates over many years, the analyst tells investors in a research note. BTIG believes Motivab s 40%-plus share in its more established markets is indicative of Establishment's potential to capture share from entrenched players in newer markets such as the U.S. and China.

Needham

Hold -> Buy

upgrade

$48

2025-05-14

Reason

Needham

Price Target

$48

2025-05-14

upgrade

Hold -> Buy

Reason

Needham upgraded Establishment Labs to Buy from Hold with a $48 price target. The firm says the easing of the trade war between the U.S. and China reduces its concern about Establishment's international business while Mia and Preserve should become more significant growth drivers outside the U.S. Management is bullish on the U.S. Motiva launch, and Needham has increased confidence that it can be a source of upside in 2025, the analyst tells investors in a research note. The firm thinks Establishment's upcoming investor day on June 12 is likely to be a positive catalyst for the shares. The stock's valuation is attractive considering the company's growth potential, contends Needham.

Needham

Mike Matson

Hold

Initiates

n/a

2025-04-14

Reason

Needham

Mike Matson

Price Target

n/a

2025-04-14

Initiates

Hold

Reason

Needham initiated coverage of Establishment Labs with a Hold rating and no price target. The company's U.S. Motiva launch should serve as a "major growth driver" and a potential source of upside while its minimally invasive procedures may expand the breast implant market, the analyst tells investors in a research note. However, the firm says Establishment's international business has been weak, and that it worries the trade war could weigh on its international growth.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Establishment Labs Holdings Inc (ESTA.O) is -22.41, compared to its 5-year average forward P/E of -31.73. For a more detailed relative valuation and DCF analysis to assess Establishment Labs Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-31.73

Current PE

-22.41

Overvalued PE

-13.36

Undervalued PE

-50.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-89.59

Current EV/EBITDA

-133.35

Overvalued EV/EBITDA

-5.53

Undervalued EV/EBITDA

-173.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.90

Current PS

5.64

Overvalued PS

10.60

Undervalued PS

5.20